The bottom line: “We’re talking about a process that’s going to take some time, but that shows great promise,” said Dr. McMurry-Heath.
You know you want to know more. Dr. Levin’s new book, Biotechnology in the Time of COVID-19, has thoughts from 27 biotech industry leaders on how they are approaching the pandemic—and it’s available now via Amazon.
More News:
Fierce Biotech: Angelini lands EU rights to Ovid's phase 3 rare disease drug
“Italy’s Angelini Pharma is paying $20 million upfront to secure a license to a drug that is due to come through a phase 3 trial in Angelman syndrome by the end of the year.”
Healthcare Finance: Stakeholders urge CMS to finalize new CAR-T therapy payment rule
“In the letter, the stakeholders argued that CAR-T therapies offer improved outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia and provides hope for many more with other hard-to-treat cancers.”
Reuters: Pharmas restart drug trials after pandemic-related declines, Medidata finds
“The research, which was prepared by clinical trial technology company Medidata, shows that the number of new subjects entering trials increased 112% in June compared with the low point in April.”
The New York Times: How koalas with an STD could help humanity
“When it comes to finding a vaccine for chlamydia, the world’s most common sexually transmitted infection, koalas may prove a key ally.”
The Washington Post: Operation Warp Speed is pushing for COVID-19 therapeutics by early fall
“New treatment options for COVID-19 could arrive months before even the most optimistic timeline for a vaccine, senior Trump administration officials said at a briefing Monday.”